Let’s talk glaucoma implants.

Allergan has been working on a sustained-release glaucoma implant.

What is it?
It’s called Bimatoprost SR and it’s a biodegradable implant that dispenses bimatoprost (aka Lumigan) for at least 4 months. It’s injected into the anterior chamber and is visible in the inferior iridocorneal angle where it slowly dispenses medication and degrades.

How much IOP reduction?
In their Phase 3 trial, it reduced IOP by 30% over 12 weeks which is similar to topical prostaglandins.

When will this be a thing?
Not until next year. Allergan plans to submit a new drug application to the FDA in 2019. (via)

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts